MMA’s stock is skyrocketing — now that there’s a Trump connection
Donald Trump Jr. is joining combat sports company MMA Inc. as a strategic advisor.
MMA’s stock is skyrocketing — now that there’s a Trump connection Read Post »
Another 1,000% gainer: CaliberCos surges on digital-asset purchase, a day after Eightco’s 3,000% gain
The 3,000% surge in Eightco Holdings’ stock on the purchase of a digital asset that can be acquired independently is
Fed is almost certain to cut rates by 25 basis points after months of debate. Why are so many people so unhappy about it?
Economists are split into opposite camps on which is more important for the Fed to battle — slower growth or
Why ASML, which makes million-dollar machines, is buying a stake in AI chatbot creator
ASML’s announcement it was buying a significant stake in a producer of one of the leading large language models has
Why ASML, which makes million-dollar machines, is buying a stake in AI chatbot creator Read Post »
‘Frenzied as ever’: This Dan Ives–led Worldcoin treasury purchase is only the latest example of market madness
The 3,000% surge in Eightco Holdings on the purchase of a digital asset that can be acquired independently is just
Why JPMorgan is warning the Fed rate cut everyone expects could sink stocks
The widely expected September Fed rate cut may have a surprise in store for investors who think stocks have nowhere
Why JPMorgan is warning the Fed rate cut everyone expects could sink stocks Read Post »
The ‘Nothing Ever Happens’ Market: How Stocks React (Or Don’t) to Geopolitical Events
Geopolitical events — terrorist acts, wars, or military intervention — can give stocks a jolt. But that doesn’t mean your
The ‘Nothing Ever Happens’ Market: How Stocks React (Or Don’t) to Geopolitical Events Read Post »
Protect Your Heart: The Surprising Power of this Simple Treatment
This one measure may be as effective as lifestyle changes or some medications for safeguarding your heart health.
Protect Your Heart: The Surprising Power of this Simple Treatment Read Post »
Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range
Novartis on Tuesday said it was buying a U.S. biotech working on a cardiovascular drug, continuing what’s been a flurry